Role of thrombotic vascular risk factors in inflammatory bowel disease

Digestive Diseases

Volumn 18, Issue 3, 2000, Pages 161-167

  Koutroubakis, Ioannis E ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Anticardiolipin antibodies; Coagulation; Crohn's disease; Factor V Leiden; Homocysteine; Thrombosis; Ulcerative colitis

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BLOOD CLOTTING FACTOR 5 LEIDEN; CARDIOLIPIN ANTIBODY; HOMOCYSTEINE; PHOSPHOLIPID ANTIBODY;

BLOOD CLOTTING; CROHN DISEASE; DISEASE ASSOCIATION; ENTERITIS; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN; HYPERCOAGULABILITY; HYPERHOMOCYSTEINEMIA; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; ULCERATIVE COLITIS; VEIN THROMBOSIS;

ANTIBODIES, ANTIPHOSPHOLIPID; BLOOD COAGULATION; FACTOR V; HOMOCYSTEINE; HUMANS; INFLAMMATORY BOWEL DISEASES; RISK FACTORS; THROMBOSIS;

EID: 0034464894     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000051389     Document Type: Review

References (77)

1. Pathogenesis of Crohn's disease
2. Granulomatous vasculitis in Crohn's disease
3. Vascular changes in Crohn's disease
4. Remodeling of vascular wall in Crohn's disease
5. Mesenteric blood flow is related to disease activity and risk of relapse in Crohn's disease: A prospective follow-up study
6. Doppler sonography of hemodynamic changes of the inferior mesenteric artery in inflammatory bowel disease: Preliminary data
7. Smoking in Crohn's disease: Effect on localisation and clinical course
8. Meta-analysis of the role of oral contraceptive agents in inflammatory bowel disease
9. Inherited disorders of coagulation appear to protect against inflammatory bowel disease
10. Paradoxical response to heparin in 10 patients with ulcerative colitis
11. Treatment of corticosteroid-resistant ulcerative colitis with heparin - A report of 16 cases
12. Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease
13. Low molecular weight heparin as adjuvant therapy in active ulcerative colitis
14. Heparin in inflammation: Potential therapeutic applications beyond anticoagulation
15. Expression of syntdecan-1 in inflammatory bowel disease and a possible mechanism of heparin therapy
16. Vascular complications of inflammatory bowel disease
17. Review article: Platelets in inflammatory bowel disease - Pathogenetic role and therapeutic implications
18. Venous thrombosis occurring in non-specific ulcerative colitis
19. Prothrombotic state and signs of endothelial lesion in plasma of patients with inflammatory bowel disease
20. Thromboembolism in inflammatory bowel disease: Role of platelets
21. Hemostatic abnormalities in inflammatory bowel disease
22. Activation of plasma contact and coagulation systems and neutrophils in the active phase of ulcerative colitis
23. Platelets and coagulation
24. Fibrinolytic split products, fibrinolysis, and factor XIII activity in inflammatory bowel disease
25. Markers of coagulation and fibrinolysis as measures of disease activity in inflammatory bowel disease
26. Dynamics of blood coagulation factor XIII in ulcerative colitis and preliminary study of the factor XIII concentrate
27. Coagulation and fibrinolysis in children, adolescents, and young adults with inflammatory bowel disease
28. Thrombotic vascular risk factors in inflammatory bowel disease
29. Coagulation studies in ulcerative colitis and Crohn's disease
30. Hemostatic alterations in inflammatory bowel disease
31. Circulating von Willebrand factor in inflammatory bowel disease
32. Prothrombin fragment 1+2 and thrombin-antithrombin III complex as markers of activation of blood coagulation in inflammatory bowel diseases
33. Determination of prothrombin activation fragments in young patients with inflammatory bowel disease
34. Factor XIIIA subunit and Crohn's disease
35. Ulcerative colitis and Crohn's disease: Factor XIII, inflammation and haemostasis
36. Deficiency of blood coagulation factor XIII in Crohn's disease
37. Arg506Gln factor V mutation and Val34Leu factor XIII polymorphism in Finnish patients with inflammatory bowel disease
38. Acquired protein C and S deficiency, inflammatory bowel disease and cerebral arterial thrombosis
39. Free protein S deficiency in patients with chronic inflammatory bowel disease
40. Free protein S deficiency in patients with Crohn's disease
41. Prothrombotic abnormalities in inflammatory bowel disease
42. Evidence for activation of coagulation in Crohn's disease
43. Thrombosis in inflammatory bowel disease: Clinical setting, procoagulant profile and factor V Leiden
44. Activated protein C resistance, thrombophilia, and inflammatory bowel disease
45. Resistance to activated protein C and low levels of free protein S in Greek patients with inflammatory bowel disease
46. Genetic and phenotypic analysis of a large (122-member) protein S-deficient kindred provides an explanation for the familial coexistence of type I and type III plasma phenotypes
47. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis
48. Antiphospholipid thrombosis syndromes: Etiology, pathophysiology, diagnosis and management
49. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor
50. Requirement of beta 2 glycoprotein I as cofactor in the binding for IgM and IgA anticardiolipin antibodies
51. Anti beta 2 glycoprotein I antibodies: Detection and association with thrombosis
52. Prevalence and clinical significance of IgG isotype anti-beta 2-glycoprotein I antibodies in antiphospholipid syndrome: A comparative study with anticardiolipin antibodies
53. Risk of thromboembolic complications in patients with inflammatory bowel disease. Study of hemostasis measurements
54. Soluble interleukin-2 receptors, antineutrophil cytoplasmic antibodies, and other autoantibodies in patients with ulcerative colitis
55. Prevalence and significance of anticardiolipin antibodies in Crohn's disease
56. Prevalence and role of anticardiolipin antibodies in Crohn disease
57. Antiphospholipid antibodies in inflammatory bowel disease
58. Anti-cardiolipin and anti-beta2-glycoprotein I antibodies in patients with inflammatory bowel disease
59. Anti-cardiolipin antibodies in patients with inflammatory bowel disease
60. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C
61. Mutation in blood coagulation factor V associated with resistance to activated protein C
62. Resistance to activated protein C as a basis for venous thrombosis
63. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism
64. Activated protein C resistance in pediatric inflammatory bowel disease
65. Thromboembolism and resistance to activated protein C in patients with inflammatory bowel disease
66. Factor V Leiden mutation is not increased in patients with inflammatory bowel disease
67. Thrombophilia and inflammatory bowel disease: Does factor V mutation have a role?
68. The factor V Leiden mutation increases the risk of venous thrombosis in patients with inflammatory bowel disease
69. An investigation of the association of the factor V Leiden mutation and inflammatory bowel disease
70. High prevalence of hyperchomocysteinemia in patients with inflammatory bowel disease: A pathogenic link with thromboembolic complications?
71. Increased prevalence of methylenetetrahydrofolate reductase C677T variant in patients with inflammatory bowel disease, and its clinical implications
72. Effect of folate supplementation on the incidence of dysplasia and cancer in chronic ulcerative colitis. A case-control study
73. 12, zinc, and copper status in outpatients with Crohn's disease: Effect of diet counseling
74. 12 metabolism
75. Homocysteine and MTHFR T677T mutation in inflammatory bowel disease
76. Hyperhomocysteinemia in Greek patients with inflammatory bowel disease
77. Factor V Leiden mutation is not increased in patients with inflammatory bowel disease